Mitogenic potentials of bestatin, amastatin, arphamenines A and B, FK-156 and FK-565 on spleen lymphocytes.

The following aminopeptidase (AP) activities were found to be associated with the surface of mouse spleen cells: Leu-AP (138 pmol/10(5) cells X minute) and AP-B (16 pmol/10(5) cells X minute with Lys-beta-naphthylamide as substrate and 21 pmol/10(5) cells X minute with Arg-beta-naphthylamide substrate); AP-A activity was not detected by the assay system applied. The immunoactive peptide bestatin inhibited the Leu-AP, while AP-B activity decreased in the presence of both arphamenines A and B and bestatin. No effects on these enzymes were caused by amastatin (an AP-A inhibitor), FK-156, FK-565 and Bu-2743E; the latter peptide turned out to be not an inhibitor of cell surface associated microsomal Leu-AP but an inhibitor of cytosolic Leu-AP. The immunoactive peptides bestatin, arphamenines A and B, and amastatin increased [3H]thymidine incorporation into spleen cells containing lymphocytes and macrophages. These mitogenic actions were not observed when macrophages were removed from the cultures or the cells had been stimulated with ConA or LPS. The lactoyl- and heptanoyl peptides FK-156 and FK-565 caused a mitogenic action on lymphocytes independently of the presence of macrophages. The inhibitor of cytosolic Leu-AP did not change the incorporation into lymphocytes.

[1]  D. Schuster,et al.  Cell Surface-Bound Leucine Aminopeptidase: Target of the Immunomodulator Bestatin , 1986 .

[2]  J. Schwartz.  Metabolism of enkephalins and the inactivating neuropeptidase concept , 1983, Trends in Neurosciences.

[3]  T. Aoyagi,et al.  Arphamenines A and B, new inhibitors of aminopeptidase B, produced by bacteria. , 1983, The Journal of antibiotics.

[4]  H. Kawaguchi,et al.  Bu-2743E, a leucine aminopeptidase inhibitor, produced by Bacillus circulans. , 1983, The Journal of antibiotics.

[5]  M. Nishida,et al.  Immunoactive peptides, FK-156 and FK-565. I. Enhancement of host resistance to microbial infection in mice. , 1983, The Journal of antibiotics.

[6]  W. Müller,et al.  Immunochemical identification of the cell surface bound leucine aminopeptidase, the target enzyme for the immunostimulant bestatin. , 1983, The Journal of antibiotics.

[7]  D. Schuster,et al.  Identification and properties of the cell membrane bound leucine aminopeptidase interacting with the potential immunostimulant and chemotherapeutic agent bestatin. , 1983, Biochemical pharmacology.

[8]  K. Nakahara,et al.  Studies on a new immunoactive peptide, FK-156. I. Taxonomy of the producing strains. , 1982, The Journal of antibiotics.

[9]  D. Schuster,et al.  Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. , 1982, International journal of immunopharmacology.

[10]  H. Umezawa.  Small molecular immunomodifiers of microbial origin : fundamental and clinical studies of bestatin , 1981 .

[11]  T. Aoyagi,et al.  Effect of bestatin on mouse immune system and experimental murine tumors. , 1980, The Journal of antibiotics.

[12]  T. Takeuchi,et al.  Mitogenic effect of bestatin on lymphocytes. , 1980, The Journal of antibiotics.

[13]  W. Müller,et al.  Activation of DNA metabolism in T-cells by bestatin. , 1979, Biochemical pharmacology.

[14]  T. Aoyagi,et al.  Amastatin, an inhibitor of aminopeptidase A, produced by actinomycetes. , 1978, The Journal of antibiotics.

[15]  A. Barrett.  Proteinases in Mammalian Cells and Tissues , 1977 .

[16]  T. Aoyagi,et al.  Aminopeptidase activities on the surface of mammalian cells. , 1976, Biochimica et biophysica acta.

[17]  T. Aoyagi,et al.  Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. , 1976, The Journal of antibiotics.

[18]  G. Glenner,et al.  A Mammalian Peptidase specific for the Hydrolysis of N-Terminal α-L-Glutamyl and Aspartyl Residues , 1962, Nature.